ALSO NOTED: CMA: Docs rely too much on pharma's spin; Faes licenses antihistamine to Italian firm;

> A Canadian Medical Association official says doctors get too much information about prescription drugs from the pharma companies themselves, and that there's a lack of impartial drug info. Report

> Spain's Faes Farma has licensed the marketing rights to its antihistamine drug Bilastina to the Italian firm Menarini. Report

> Health officials in the Phillipines say a recent compromise on prescription-drug prices isn't enough; they want the islands to nationalize their pharma industry. Report

> The FDA wants the over-the-counter spermicide nonoxynol-9 to carry a new warning: that the product does not protect against HIV and other sexually transmitted diseases. Report

> CV Therapeutics got the FDA's blessing on a new label for its angina drug Ranexa. Report

> Bioserve is hopping on the pharmacogenomics bandwagon. Report

> Analysts applauded Canada's BioMS after it scored a rich licensing deal with Eli Lilly. Lilly gains commercialization rights in exchange for a whopping $87 million up-front fee and milestones reaching up to $410 million. Report

> Denmark's Santaris Pharma has banked $30 million from its latest venture round. Report

> Up to now, researchers have been primarily interested in studying efficacy and safety in clinical trials. After today, you may have to start adding efficiency to the list of R&D focuses. Report

And Finally... By genetically engineering mice, scientists in Japan were able to switch off their fear of cats. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.